© CEOCFO Magazine -
CEOCFO Magazine, PO Box 340
Palm Harbor, FL 34682-
Lynn Fosse, Senior Editor
Steve Alexander, Associate Editor
Bud Wayne, Marketing
& Production Manager
Christy Rivers -
Dr. Andrea Small-
President & CSO
GB Sciences, Inc.
Interview conducted by:
Lynn Fosse, Senior Editor
Published – November 14, 2022
CEOCFO: Dr. Small-
We think that our approach is quite novel in that there have been companies striving to bring pharmaceutical products to market by looking within traditional medicines, but they are not looking to harness the potential within traditional medicine in a holistic way informed by the epistemology of these medicines, which relies on combinations of ingredients working together. In contrast, the western pharmaceutical approach to utilizing plant-
We believe that by augmenting drug discovery with modern in silico processes, we should be able to create a more complex in silico model of human physiology, and, ultimately, utilize the ‘side-
CEOCFO: Why has this not been thought of before?
Approximately 65% of the world uses traditional medicines to treat disease, some in conjunction with Western medicines, but others rely on traditional medicines as their primary medicines. I think that in the US and other parts of the western world, we do not realize the true potential of traditional medicines or that they are currently helping people globally. Traditional medicine, by definition, is very localized and based on what grows in your area; whereas the kind of system that we are trying to create would take some of the principles of traditional medicine but expand upon it so that you could globalize these treatments.
CEOCFO: Will the US FDA come into this at some point?
CEOCFO: How are you preparing and why do you think the US FDA is ready to look at this in a fair way?
Not only are we reducing the number of ingredients from the original traditional medicines in our novel MEM therapies, but we are also using intelligent design to define the interactions of these active ingredients. Simply put, we are looking for molecular synergies within the active ingredients in our MEM. We have demonstrated that the efficacy of each minimum essential mixture is greater than the sum of the effects of the individual active ingredients. It is by utilizing this definition of synergy that we have been able to patent our minimal essential mixtures. Because of the molecular synergies, we can demonstrate that there is increased effectiveness, which is not only a great way to get over the obviousness claim at the USPTO, but it also means you are making more effective medicines, so it is a win/win.
In the manufacturing of our MEM, we are also substituting synthetic homologues into the mixtures instead of the plant-
In summary, we are trying to harness the therapeutic power of medicinal plants by reducing the formulation complexity down to Minimum Essential Mixtures (MEM), demonstrating the effectiveness of the molecules working together, and substituting synthetic copies of the plant-
Lastly, we are formulating our plant-
For our chronic pain formulations, we are working with the University of Seville in Spain to develop time-
Not only are we striving to create non-
CEOCFO: How do you decide what to work on?
CEOCFO: Do you have products available now? What does the business side look like?
Research funding and cannabis plant materials were the two things that were the hardest to come by when I was doing academic research on cannabis. At that time, there was only one place in the country allowed to grow cannabis for research and there was a very complicated series of written permissions required to have it sent for your research. It was equally hard to get funding, especially if you were proposing to demonstrate any therapeutic benefits from cannabis. Back in the day when I did my graduate work, the only place you could get money to do cannabis work was through a part of the NIH called NIDA, which is the National Institute for Drugs of Abuse. Because NIDA’s main mission was to research the harmful effects of drugs of abuse, if you were applying for their grant program you had to be looking for data supporting the hypothesis that cannabis was harmful. It was difficult for them to give grants for studying the therapeutic potential of the plant at the time. NIDA has changed their granting policies since then, but this was the way it was when I was starting out in the early 2000s.
When I joined the company, our goal was to produce cannabis and cannabis-
CEOCFO: What is your plan for the next six months to a year?
CEOCFO: How do you deal with some of the frustration when you know you have ideas that could make a difference in peoples’ lives and it is a long and arduous process to get them into use?
CEOCFO: From the perspective of the investment and medical communities, with so many options for people to consider, why should GB Sciences standout?
A more pragmatic way to view the value that GB Sciences’ offers is to look at the significant milestones we have coming up in our biopharmaceutical pipeline. We have come a long way, and we are getting closer to the clinic every day. Shareholders will enjoy an increased valuation during our transition from a pre-
GB Sciences, Inc. | Dr. Andrea Small-
“In summary, we are trying to harness the therapeutic power of medicinal plants by reducing the formulation complexity down to Minimum Essential Mixtures (MEM), demonstrating the effectiveness of the molecules working together, and substituting synthetic copies of the plant-
Dr. Andrea Small-